	1.	Article Title: The Antibody Assay in Suspected Autoimmune Encephalitis From Positive Rate to Test Strategies
	•	Line(s): 1-2
	•	Section: Title
	•	Quote(s): “The Antibody Assay in Suspected Autoimmune Encephalitis From Positive Rate to Test Strategies”
	2.	Publication Year: 2022
	•	Line(s): 15-16
	•	Section: Journal Citation
	•	Quote(s): “Frontiers in Immunology, Published: 23 February 2022”
	3.	Region: Asia
	•	Line(s): 26-28
	•	Section: Methods
	•	Quote(s): “Patients who were diagnosed with suspected autoimmune encephalitis in Guizhou Province, China.”
	4.	Country: China
	•	Line(s): 26-28
	•	Section: Methods
	•	Quote(s): “Patients who were diagnosed with suspected autoimmune encephalitis in Guizhou Province, China.”
	5.	Study Coverage Area: Single region (Guizhou Province, China)
	•	Line(s): 26-28
	•	Section: Methods
	•	Quote(s): “Patients who were diagnosed with suspected autoimmune encephalitis in Guizhou Province.”
	6.	Study Design: Retrospective observational study
	•	Line(s): 30-34
	•	Section: Methods
	•	Quote(s): “Patients diagnosed with suspected autoimmune encephalitis in Guizhou Province between June 1, 2020, and June 30, 2021, were included in this study.”
	7.	Population Cohort: Patients with suspected autoimmune encephalitis
	•	Line(s): 30-34
	•	Section: Methods
	•	Quote(s): “Patients diagnosed with suspected autoimmune encephalitis… who had anti-neuronal autoantibodies detected.”
	8.	Population Characteristics: Mixed age and sex distribution
	•	Line(s): 94-96
	•	Section: Results
	•	Quote(s): “A total of 263 patients with suspected AE were included, 58.2% males, median age 33 years (range 1-84 years).”
	9.	Data Source: Laboratory test records from Guizhou KingMed Diagnostics Group
	•	Line(s): 30-34
	•	Section: Methods
	•	Quote(s): “Patients diagnosed with suspected AE… were tested at Guizhou KingMed Diagnostics Group.”
	10.	Prospective or Retrospective: Retrospective
	•	Line(s): 30
	•	Section: Methods
	•	Quote(s): “A retrospective study was conducted.”
	11.	Sites or Centers Involved: Six medical centers in Guizhou Province
	•	Line(s): 34-36
	•	Section: Methods
	•	Quote(s): “The data came from six medical centers, which have qualifications for the diagnosis of AE in the study sites.”
	12.	Study Duration: June 2020 – June 2021
	•	Line(s): 30-32
	•	Section: Methods
	•	Quote(s): “Patients diagnosed with suspected autoimmune encephalitis in Guizhou Province between June 1, 2020, and June 30, 2021.”
	13.	Population Ethnicity: NR
	14.	Disease Analysis: Autoimmune encephalitis (AE)
	•	Line(s): 30-32
	•	Section: Methods
	•	Quote(s): “Patients diagnosed with suspected autoimmune encephalitis…”
	15.	Classification or Diagnosis: Antibody-positive AE based on laboratory assay
	•	Line(s): 82-86
	•	Section: Methods
	•	Quote(s): “Anti-neuronal antibodies detected using laboratory methods.”
	16.	Diagnosis Criteria Details: Based on published AE diagnostic criteria
	•	Line(s): 82-86
	•	Section: Methods
	•	Quote(s): “Patients who were diagnosed with suspected AE according to the published AE diagnostic criteria.”
	17.	Disease Phase: NR
	18.	Cohort Age Group: Mixed (pediatric, adult)
	•	Line(s): 94
	•	Section: Results
	•	Quote(s): “Median age of 33 years (range 1-84 years).”
	19.	Female Percentage in Cohort: 41.8%
	•	Line(s): 94
	•	Section: Results
	•	Quote(s): “58.2% (153/263) were males, meaning 41.8% were females.”
	20.	Patient Number of Autoimmune Encephalitis: 263 patients with suspected AE, 26 antibody-positive cases
	•	Line(s): 94
	•	Section: Results
	•	Quote(s): “A total of 263 patients with suspected AE were included, and 26 were antibody-positive.”
	•	Subtypes and Patient Numbers:
	•	Anti-NMDAR: 12 patients
	•	Anti-Caspr2: 8 patients
	•	Other antibodies: 6 patients
	21.	Follow-up Period: NR
	22.	Age of Patients by Subtype:
	•	Subtype: Anti-NMDAR
	•	Mean: NR
	•	SD: NR
	•	Median: NR
	•	IQR: NR
	•	Subtype: Anti-Caspr2
	•	Mean: NR
	•	SD: NR
	•	Median: NR
	•	IQR: NR
	23.	Age of Diagnosis by Subtype: NR